Compare Organon & Co. Common Stock (OGN) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Open Text Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Open Text Corporation trades at $24.96 (market cap $6.02B). The key difference: Open Text Corporation is the larger of the two by market cap, and Open Text Corporation pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Open Text Corporation for 24 Days on average.
| OGN | OTEX | |
|---|---|---|
Market Cap | $3.62B | $6.02B |
Volume | 2,892,999 | 1,820,095 |
Sector | Health | Technology |
52-Week High | $13.81 | $39.69 |
52-Week Low | $5.70 | $20.01 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.04B | $11.03B |
Dividend Yield | 0.58% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
OpenText (OTEX) trades at $24.95, up 3.18% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 9.67, robust 73.74% gross margins, and consistent earnings beats in recent quarters. Recent debt restructuring activities and strategic AI partnerships with Cohere highlight management's focus on growth optimization and technological advancement.
The outlook remains positive with a consensus price target of $28.30 offering 13% upside potential. Key risks include high debt levels and competitive pressures in the enterprise software sector. Analyst sentiment leans bullish with 42% buy ratings, though the stock faces near-term resistance at the $25 level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
